non-opioid alternative to current IV-based cataract surgery sedation protocols, which generally involve the administration of opioids,” said Dr Larry Dillaha, Chief Executive Officer of Melt.
Melt Pharmaceuticals has reported encouraging topline results from its Phase III trial of MELT-300, a non-intravenous, non-opioid sedation tablet for cataract surgery. The pivotal study's design ...
The trial involved over 530 patients across 13 US clinical sites. Credit: Lucky Business/Shutterstock. Melt Pharmaceuticals has reported encouraging topline results from its Phase III trial of ...
MELT-300, a non-IV, non-opioid sedation tablet, showed positive Phase 3 results for cataract surgery, supporting FDA ...
a non-IV, non-opioid tablet for procedural sedation during cataract surgery. Based on a Special Protocol Assessment agreement reached with the U.S. Food and Drug Administration earlier this year ...
Background: To compare the clinical efficacy of lidocaine 2% with tetracaine 0.5% for cataract surgery ... cataract cases eligible for topical anesthesia, were randomly assigned to receive ...
Royal College of Ophthalmologists' National Ophthalmology Database study of cataract surgery: report 11, techniques and complications of local anesthesia for cataract surgery in the United Kingdom.
Melt Pharmaceuticals announced positive topline results of its pivotal Phase 3 study evaluating the safety and efficacy of its lead product ...